Duality Advisers LP Invests $5.13 Million in DexCom, Inc. (NASDAQ:DXCM)

Duality Advisers LP acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the 4th quarter, HoldingsChannel reports. The fund acquired 41,321 shares of the medical device company’s stock, valued at approximately $5,128,000.

Several other institutional investors and hedge funds have also made changes to their positions in DXCM. Norges Bank acquired a new position in shares of DexCom during the 4th quarter worth about $421,378,000. Winslow Capital Management LLC acquired a new stake in shares of DexCom in the 3rd quarter valued at about $173,120,000. Vaughan Nelson Investment Management L.P. boosted its position in shares of DexCom by 16,943.0% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 1,459,730 shares of the medical device company’s stock valued at $136,193,000 after purchasing an additional 1,451,165 shares during the period. 1832 Asset Management L.P. acquired a new stake in shares of DexCom in the 4th quarter valued at about $151,538,000. Finally, Clearbridge Investments LLC boosted its position in shares of DexCom by 304.3% in the 1st quarter. Clearbridge Investments LLC now owns 1,318,079 shares of the medical device company’s stock valued at $674,329,000 after purchasing an additional 992,049 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Performance

DXCM traded down $3.59 on Friday, hitting $130.71. 2,859,646 shares of the company traded hands, compared to its average volume of 2,337,474. The company has a 50 day moving average of $129.55 and a 200-day moving average of $117.04. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18. The stock has a market capitalization of $50.39 billion, a PE ratio of 99.78, a PEG ratio of 2.25 and a beta of 1.20. DexCom, Inc. has a 12-month low of $74.75 and a 12-month high of $142.00.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.07. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The company’s revenue for the quarter was up 26.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.34 EPS. Sell-side analysts anticipate that DexCom, Inc. will post 1.76 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Raymond James upped their target price on DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 23rd. Royal Bank of Canada assumed coverage on DexCom in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price for the company. UBS Group upped their target price on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. StockNews.com raised DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Finally, Citigroup upped their target price on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $141.40.

Insider Transactions at DexCom

In other news, CFO Jereme M. Sylvain sold 3,363 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the transaction, the chief financial officer now directly owns 71,142 shares of the company’s stock, valued at approximately $8,304,405.66. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CFO Jereme M. Sylvain sold 3,363 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total value of $392,562.99. Following the sale, the chief financial officer now owns 71,142 shares in the company, valued at approximately $8,304,405.66. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Sadie Stern sold 20,321 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total value of $2,715,088.81. Following the completion of the sale, the executive vice president now owns 80,441 shares in the company, valued at approximately $10,747,722.01. The disclosure for this sale can be found here. In the last three months, insiders sold 189,375 shares of company stock valued at $25,530,859. Corporate insiders own 0.41% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.